Ryufin

Ion Beam Applications SA

Belgium · BE0003766806 · reports in EUR · Europe

The answers

From the annual report for the year to Dec 31, 2025. Each line says what it is based on.

Is it growing?Good
Revenue +24% in the year to Dec 31, 2025, on the year before.
Is it a good business?Fair
It earned 10% on its shareholders' equity in the year to Dec 31, 2025.
Is it safe?To watch
Equity is 18% of its assets, and operations used cash in the year.
Is the price fair?n/a
Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.

The year

Year to Dec 31, 2025, consolidated, in EUR.

€620M

revenue

4.5%

operating margin

€13M

net profit

Year by year

As filed; an earlier year can differ from its own report when the company restated it.

Dec 2022Dec 2023Dec 2024Dec 2025
Revenue€361M€429M€498M€620M
Operating profit€5M€5M€20M€28M
Earnings per share€0.21−€3128.00n/a€0.43
Dividend per sharen/a€0.21n/a€0.24
Cash from operations€22M−€20M−€11M−€26M
Capital spending€3M€5M€4M€9M
Cash€158M€109M€72M€65M
Total assets€624M€598M€616M€691M
Equity€116M€106M€111M€127M

What they do

In the company's own words, from the annual report.

1.1. ENTITÉ PRÉSENTANT LES ÉTATS FINANCIERS CONSOLIDÉS Ion Beam Applications SA (la « Société » ou la « Société Mère »), fondée en 1986, et ses filiales (ensemble, le « Groupe » ou « IBA ») conçoit, produit et commercialise des solutions innovantes pour le diagnostic et le traitement du cancer et d’autres maladies graves, ainsi que pour des applications industrielles telles que la stérilisation de dispositifs médicaux.

Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.